BRAF and metastatic melanoma: While for some drugs the variation in drug response can be explained by a very specific mutation (for instance, BRAF V600E mutation is a strong predictor for response to Vemurafenib in metastatic melanoma [4]), for many drugs the knowledge of the mechanism of action is missing.